Abstract

Our scientists have developed several MILLIPLEX^®
and Single Molecule Counting (SMC™) based SARS-CoV-2-specific immunoassay
kits in response to the COVID-19 research community’s growing needs for
research tools used to further our understanding of the novel coronavirus. These
qualitative Research Use Only (RUO) assays, which can detect antibodies against
SARS-CoV-2 antigens in human serum or plasma samples, are intended to empower
researchers performing vaccine efficacy, epidemiology, and population
studies.  Our new MILLIPLEX^® SARS-CoV-2
panels can facilitate simultaneous detection of the SARS-CoV-2 Spike S1, Spike
S2, Receptor Binding Domain (RBD), and Nucleocapsid (N) proteins and
antigen-specific IgM, IgG, or IgA antibody responses on the Luminex^®
multiplex platform. They are well suited for examining the immune response to the virus over the
course of infection and recovery from COVID-19.  Meanwhile, our SMC™ SARS-CoV-2 kits offer the ability
to characterize viral antigen specific humoral immunity with greater
sensitivity, such as in cases involving acute infections and subclinical immune
responses.  For these new assays, data
are presented from human patient samples sets confirmed positive or negative
for COVID-19 by SARS-CoV-2 PCR tests. 
Overall, our new MILLIPLEX^® and SMC™ assays can assist in
COVID-19 research efforts to help society overcome the current global pandemic.